Ask VialBase
Research

A Study of Semaglutide in Early Alzheimer's Disease — VialBase Research

Trial Summary

Phase 2 study evaluating oral or subcutaneous semaglutide in patients with early Alzheimer’s disease. This trial builds on epidemiological data and preclinical evidence suggesting GLP-1 receptor agonists may have neuroprotective effects, reduce neuroinflammation, and improve insulin signaling in the brain.

Design

  • Type: Randomized, double-blind, placebo-controlled
  • Population: Adults with early-stage Alzheimer’s disease (MCI or mild dementia due to AD)
  • Arms: Semaglutide vs. placebo
  • Duration: Likely 2+ years of treatment with cognitive and biomarker endpoints
  • Key inclusion: Amyloid-positive PET or CSF biomarkers confirming AD pathology

Key Outcomes

Not yet recruiting; no results available.

Significance for Peptide Research

This trial is a landmark moment for GLP-1 agonist repurposing. If semaglutide shows cognitive benefits in AD, it would validate the neuroinflammation-metabolism-neurodegeneration axis hypothesis and open a massive new therapeutic area for incretin-based peptides. The SELECT trial already showed cardiovascular benefits; CNS effects would further expand the multi-organ impact profile of GLP-1 RAs. Watch for interim biomarker data (tau PET, amyloid PET, plasma p-tau) before full cognitive readouts.

See Also